Deals
WeightWatchers Enters Weight Loss Drug Market With Acquisition
- Acquisition adds WeightWatchers to crowded obesity drug market
- CEO Sistani says move isn’t a pivot but extension of mission
This article is for subscribers only.
WW International Inc. looked at more than 30 different startups that prescribe obesity medications before acquiring the telemedicine company Sequence last month, Chief Executive Officer Sima Sistani said.
“They have built a tech stack better than anyone else,” she said in a Bloomberg Businessweek on Bloomberg Radio interview Thursday. “These medications are really expensive and Sequence has built out a preauthorization engine, so essentially putting the insurance process on tech rails.”